King acquires exclusive rights to EpiPen in Canada

By Lisa Kerner

Erie, Pa., March 2 - King Pharmaceuticals, Inc. said it has acquired exclusive rights to market and sell EpiPen (epinephrine injection) in Canada from Allerex Laboratory Ltd.

The company will pay Allerex $25 million plus royalties on sales of EpiPen in Canada. Net sales of the product totaled roughly $21.2 million in Canada during 2004, according to a company news release.

King manufactures auto-injectors for the self-administration of injectable drugs. EpiPen administers epinephrine, an emergency treatment for allergic reaction (anaphylaxis). If untreated, severe anaphylaxis can be fatal within minutes.

"Thousands of adults and children benefit from EpiPen, the number-one prescribed self-administered treatment for life-threatening anaphylaxis," King's chief commercial officer Steve Andrzejewski said in the release.

"We are excited to expand our existing EpiPen franchise to include the rights to market and sell this emergency self-administered product in Canada."

King, based in Bristol, Tenn., develops and in-licenses novel branded prescription products.

\

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.